Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.
about
Plasma interleukin-27 (IL-27) levels are not modulated in patients with chronic HIV-1 infectionInterleukin-27 Enhances the Potential of Reactive Oxygen Species Generation from Monocyte-derived Macrophages and Dendritic cells by Induction of p47phoxIdentification of Interleukin-27 (IL-27)/IL-27 Receptor Subunit Alpha as a Critical Immune Axis for In Vivo HIV Control.Regulation and Immune Function of IL-27.Interferons and beyond: Induction of antiretroviral restriction factors.
P2860
Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.
@en
Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.
@nl
type
label
Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.
@en
Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.
@nl
prefLabel
Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.
@en
Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.
@nl
P2093
P2860
P1476
Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection.
@en
P2093
Sanjay Swaminathan
Tomozumi Imamichi
P2860
P304
P356
10.1016/J.CYTOGFR.2013.07.001
P577
2013-08-17T00:00:00Z